Vir Biotechnology Inc (VIR)

Operating profit margin

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Operating income (ttm) US$ in thousands -517,588 -517,554 -485,694 -571,515 -662,405 -695,791 -314,095 -324,131 833,070 1,555,324 1,306,975 1,593,214 420,751 -259,405 -293,635 -383,703 -296,980 -252,335 -212,400 -219,118
Revenue (ttm) US$ in thousands 73,109 78,618 72,140 56,343 46,679 51,681 427,211 397,246 1,580,474 2,368,441 2,099,722 2,316,395 1,087,060 277,605 175,080 67,363 67,245 67,315 67,364 1,181
Operating profit margin -707.97% -658.31% -673.27% -1,014.35% -1,419.06% -1,346.32% -73.52% -81.59% 52.71% 65.67% 62.25% 68.78% 38.71% -93.44% -167.71% -569.60% -441.64% -374.86% -315.30% -18,553.60%

December 31, 2024 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $-517,588K ÷ $73,109K
= -707.97%

The operating profit margin of Vir Biotechnology Inc has shown significant fluctuations over the reported periods. The company experienced negative operating profit margins ranging from -18,553.60% to -1,419.06% in the early years, indicating that operating expenses exceeded the gross profit by a significant margin.

However, there was a notable improvement in the operating profit margin towards the end of 2021 and into 2022, with margins turning positive, reaching levels of 38.71% to 68.78%. This improvement suggests that the company successfully managed its operating expenses relative to its revenue during this period.

Nevertheless, the operating profit margin took a sharp downturn in the subsequent periods, falling back into negative territory. The margins decreased significantly, hitting lows of -1,346.32% to -707.97% in the latter part of 2024, indicating challenges in controlling operating costs relative to revenue generation.

Overall, the trend in the operating profit margin of Vir Biotechnology Inc reflects a volatile performance, with periods of improvement followed by setbacks. It suggests that the company may need to focus on maintaining cost efficiency and optimizing its operational performance to ensure sustainable profitability in the future.